Plain-English translation of NCT06204315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing stereotactic radiosurgery (a highly focused radiation treatment) for people whose cancer has spread to their spine and is pressing on the spinal cord or nearby nerves. The procedure delivers radiation very precisely to kill cancer cells while protecting healthy nerve tissue. Researchers want to confirm that this treatment is safe and can relieve pain and improve quality of life.
When cancer spreads to the spine, it can press on the spinal cord and cause pain, numbness, or weakness in the legs and arms. Standard radiation therapy is not always precise enough for these sensitive areas. This trial exists to prove that this newer, more targeted radiation approach can effectively treat spinal cancer while keeping nerve damage to less than 1%.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would receive a single treatment of stereotactic radiosurgery — a non-surgical procedure where you lie still while a machine delivers precise radiation to your spinal tumor. Before treatment, you'll have imaging scans to plan the therapy carefully. After treatment, you'll come back for follow-up visits where doctors check your pain levels, nerve function, and overall quality of life using questionnaires and imaging scans. The study aims to track how well you're doing and whether you're able to walk and manage daily activities.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Brainlab AG
Enrollment target
~60 participants
Started
November 2024
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amol Ghia, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.